24 May 2022 - Noveome Biotherapeutics today announced that the U.S. FDA has granted rare paediatric disease designation and orphan drug designation to the company’s lead product ST266 for the treatment of necrotising enterocolitis.
ST266 is a cell free sterile biologic solution containing hundreds of proteins and other factors at physiologic levels.